Category: Comparative Effectiveness Research / Health Technology Assessment

Although it is difficult to be precise about the nature of the articles in this category (see Luce et al The Milbank Quarterly 2010;88: 256-276 for one taxonomy), ISPOR Journals welcome articles presenting information that can assist those deciding on the efficient and equitable allocation of health care resources by examining the relative value of interventions. In some cases relative value may be addressed by considering only clinical outcomes, although normally it will involve considering, in addition, patient reported outcomes/quality of life measures and impacts on resource utilization. Articles in this category can report the results of primary research, or systematic reviews of the existing literature.

ASSURE SAFETY IN INTRAVENOUS MEDICATION USE IN CHINA

Beijing, China – Chinese inpatients have experienced overuse of intravenous medications, with a total of 10.4 billion infusion bottles for 1.3 billion Chinese people annually, approximately 8 infusion bottles per capita in 2009. However, few studies have yet been published

Posted in Comparative Effectiveness Research / Health Technology Assessment, ISPOR News & Press, Value in Health Regional Issues Tagged with: , , ,

Risk Sharing To Fund Innovative Health Care Technologies: Lessons From The Airline Industry

Edmonton, AB, Canada – The evidence for innovative health technologies is, by definition, highly uncertain and their acquisition costs are frequently an order of magnitude greater than the technologies they replace. Health care payers struggle to manage the budget impact of

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , ,

Does Outcomes Research Reduce Policy Maker Uncertainty?

Rotterdam, The Netherlands – Health care payers increasingly request additional data from clinical practice to assess whether a drug is worth public spending. The data gathered should reduce the initial uncertainty regarding the clinical and economic performance of expensive drugs in a

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , ,

Reviewing Evidence For Use In Cost Effectiveness Models

Sheffield, United Kingdom – Health technology assessments typically require the development of a cost-effectiveness model which necessitates the identification, selection and use of other types of information beyond clinical effectiveness evidence in order to populate the model parameters. The reviewing activity

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , ,

Evaluating Diagnostic Strategies Involving Multiple Tests

Leicester, UK – It is essential that the relationships between diagnostic tests are understood in order to ensure the most effective diagnoses of diseases, as they rarely perform independently. To date, both clinical and economic evaluations of combinations of diagnostic tests

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , , ,

Bayesian Methods Can Help To Bring Science Closer To Policy

Nijmegen, The Netherlands – A gap often exists between the questions that policy-makers face and the answers that science provides. Typically, science offers bits and pieces of information that are, at best, partially relevant to the policy problem under consideration.

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , , ,

Common Adverse Effects And Health Care Costs In HIV Patients On Antiretroviral Therapies

Washington, DC, USA – Human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. More than one million people in the United States are affected by HIV. There is currently no cure for HIV; however, antiretroviral therapies such as

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , , , ,